Inogen (INGN) Total Non-Current Liabilities (2013 - 2026)
Inogen's (INGN) quarterly Total Non-Current Liabilities came in at $92.7 million in Q2 2026, down 2.95% year-over-year from $95.6 million in Q2 2025, and up 9.59% quarter-over-quarter from $84.6 million in Q1 2026.
Analysis
Inogen (INGN) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Inogen (INGN) has reported Total Non-Current Liabilities for 14 consecutive years, with $92.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 2.95% year-over-year to $92.7 million in Q2 2026; TTM through Jun 2026 was $92.7 million, a 2.95% decrease from a year earlier, with the FY2025 full-year figure at $88.2 million, down 16.77% from the prior year.
- Total Non-Current Liabilities was $92.7 million for Q2 2026 at Inogen, up from $84.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $111.1 million in Q3 2022 and troughed at $84.6 million in Q1 2026.
- A 5-year average of $98.9 million and a median of $97.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities fell 18.25% in 2023 and grew 21.21% in 2024, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $95.5 million in 2022, then advanced by 12.58% to $107.5 million in 2023, then fell by 1.45% to $106.0 million in 2024, then decreased by 16.77% to $88.2 million in 2025, then advanced by 5.16% to $92.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $92.7 million (Q2 2026), $84.6 million (Q1 2026), and $88.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 40.46 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 21.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 17.56 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 2.57 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 6.34 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 3.68 Bn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Inogen | 142.58 Mn | 37.04 Mn | 43.27 Mn | 92.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.75 Mn |
| Mar 31, 2026 | 84.63 Mn |
| Dec 31, 2025 | 88.20 Mn |
| Sep 30, 2025 | 92.02 Mn |
| Jun 30, 2025 | 95.56 Mn |
| Mar 31, 2025 | 94.23 Mn |
| Dec 31, 2024 | 105.98 Mn |
| Sep 30, 2024 | 104.59 Mn |
| Jun 30, 2024 | 105.43 Mn |
| Mar 31, 2024 | 108.27 Mn |
| Dec 31, 2023 | 107.53 Mn |
| Sep 30, 2023 | 99.74 Mn |
| Jun 30, 2023 | 86.98 Mn |
| Mar 31, 2023 | 92.36 Mn |
| Dec 31, 2022 | 95.51 Mn |
| Sep 30, 2022 | 111.11 Mn |
| Jun 30, 2022 | 106.39 Mn |
| Mar 31, 2022 | 109.76 Mn |
| Dec 31, 2021 | 112.04 Mn |
| Sep 30, 2021 | 113.33 Mn |